Podcast: Developing Therapies with Transomics

Ayesha Rashid and the editorial team at the Xtalks Life Science podcast spoke with Dr. Samantha Dale Strasser, chief scientific officer and co-founder of biotech start-up Pepper Bio. The company is working to develop therapeutics in the areas of oncology, neurodegenerative disease and inflammatory conditions using a ‘transomics’ drug discovery approach. This involves the integrated analysis of several layers of biological data, including genomic, proteomic, transcriptomic and phosphoproteomic data using…

Comments Off on Podcast: Developing Therapies with Transomics

Podcast: Using Transomics to Treat the Untreatable

William Schoeffler, host of the Human Interest podcast, sits down with co-founder and CEO of Pepper Bio, to discuss the company’s computational drug discovery platform and how its transomics approach can lead to the discovery and development of safer and more effective drugs. Listen here to learn how Pepper is changing drug discovery. Source: Human Interest Podcast // See original post here.

Comments Off on Podcast: Using Transomics to Treat the Untreatable

Podcast: Changing Drug Discovery with Transomics

Neil Littman from the Bioverge Podcast sits down with Samantha Dale Strasser, co-founder and chief scientific officer of Pepper Bio, to discuss the company’s computational drug discovery platform and how its transomics approach can lead to the discovery and development of safer and more effective drugs. Listen here to learn how Pepper is changing drug discovery. Source: Bioverge Podcast // See original post here.

Comments Off on Podcast: Changing Drug Discovery with Transomics

The Root Cause Of Pharma’s Drug Development Problem

Jon Hu Forbes Councils Member Everyone likes to point fingers at big pharma. They’ll point to how much money it takes to develop a single drug (up to $2.8 billion on average)—or point to how a drug caused severe, long-term side effects that result in it coming off the market—ultimately throwing that money down the drain. But ironically, they’re missing the point. The problem isn’t the cost; the cost is an effect…

Comments Off on The Root Cause Of Pharma’s Drug Development Problem

Stanford Lab Aligns With Pepper Bio To Target Tough Cancers

The drug discovery firm will work with the Dean Felsher laboratory, using the company's transomics platform to discover therapies for untreatable cancers. Researchers at Stanford University's Dean Felsher laboratory have announced plans to collaborate with drug discovery company Pepper Bio in an effort to identify therapeutic targets for untreatable lymphatic and liver cancers. With the help of Pepper Bio's platform on phosphoproteomics, the collaborators reportedly aim to identify and validate…

Comments Off on Stanford Lab Aligns With Pepper Bio To Target Tough Cancers

Pepper Bio Partners with Stanford’s Felsher Lab to Identify Therapy Targets for Untreatable, MYC Addicted Lymphatic and Liver Cancers

Leveraging Pepper Bio’s transomics platform, Dean Felsher’s research team will translate academic findings for the development of more efficacious therapies for lymphoma and hepatocellular carcinoma Today, Pepper Bio, the world’s first transomics drug discovery company, announced a collaboration with the Dean Felsher Laboratory at Stanford University. Leveraging Pepper Bio’s unique platform on phosphoproteomics, the two teams aim to identify and validate novel targets for hepatocellular carcinoma and lymphoma within the year. Read on…

Comments Off on Pepper Bio Partners with Stanford’s Felsher Lab to Identify Therapy Targets for Untreatable, MYC Addicted Lymphatic and Liver Cancers